Abstract
| Original language | English |
|---|---|
| Pages (from-to) | e609-e614 |
| Journal | Clinical Genitourinary Cancer |
| Volume | 15 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2017 |
Fingerprint
Keywords
- Chromophobe RCC
- First-line treatment
- nccRCC
- Papillary RCC
- Pazopanib
Cite this
First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study. / Buti, S.; Bersanelli, M.; Maines, F.; Facchini, G.; Gelsomino, F.; Zustovich, F.; Santoni, M.; Verri, E.; De Giorgi, U.; Masini, C.; Morelli, F.; Vitale, M.G.; Sava, T.; Prati, G.; Librici, C.; Fraccon, A.P.; Fornarini, G.; Maruzzo, M.; Leonardi, F.; Caffo, O.
In: Clinical Genitourinary Cancer, Vol. 15, No. 4, 2017, p. e609-e614.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study
AU - Buti, S.
AU - Bersanelli, M.
AU - Maines, F.
AU - Facchini, G.
AU - Gelsomino, F.
AU - Zustovich, F.
AU - Santoni, M.
AU - Verri, E.
AU - De Giorgi, U.
AU - Masini, C.
AU - Morelli, F.
AU - Vitale, M.G.
AU - Sava, T.
AU - Prati, G.
AU - Librici, C.
AU - Fraccon, A.P.
AU - Fornarini, G.
AU - Maruzzo, M.
AU - Leonardi, F.
AU - Caffo, O.
N1 - Export Date: 29 August 2017 Correspondence Address: Bersanelli, M.; University Hospital of Parma, Medical Oncology, Via Gramsci 14, Italy; email: bersamel@libero.it
PY - 2017
Y1 - 2017
N2 - Micro-Abstract In this retrospective study we focused on a subgroup of rare tumors, such as non–clear-cell renal cancers, with the aim to provide evidence of activity and feasibility of a multityrosine kinase inhibitor, pazopanib, as a first-line treatment alternative to the widely used sunitinib. Our conclusions support the use of pazopanib in this subgroup, awaiting prospective results of ongoing clinical trials. © 2016 Elsevier Inc.
AB - Micro-Abstract In this retrospective study we focused on a subgroup of rare tumors, such as non–clear-cell renal cancers, with the aim to provide evidence of activity and feasibility of a multityrosine kinase inhibitor, pazopanib, as a first-line treatment alternative to the widely used sunitinib. Our conclusions support the use of pazopanib in this subgroup, awaiting prospective results of ongoing clinical trials. © 2016 Elsevier Inc.
KW - Chromophobe RCC
KW - First-line treatment
KW - nccRCC
KW - Papillary RCC
KW - Pazopanib
U2 - 10.1016/j.clgc.2016.12.024
DO - 10.1016/j.clgc.2016.12.024
M3 - Article
VL - 15
SP - e609-e614
JO - Clinical Genitourinary Cancer
JF - Clinical Genitourinary Cancer
SN - 1558-7673
IS - 4
ER -